Journalartikel

Jahr der Veröffentlichung: 2021

Seiten: 6-30

Zeitschrift: British Journal of Pharmacology

Bandnummer: 178

Heftnummer: 1

ISSN: 0007-1188

eISSN: 1476-5381

Open Access Status: Hybrid

DOI Link: https://doi.org/10.1111/bph.15016

Verlag: Wiley

Abstract: 
Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. However, for the vast majority of patients, PAH remains a life-limiting illness with no prospect of cure. PAH is characterised by pulmonary vascular remodelling. Current research focusses on targeting the underlying pathways of aberrant proliferation, migration, and apoptosis. Despite success in preclinical models, using a plethora of novel approaches targeting cellular GPCRs, ion channels, metabolism, epigenetics, growth factor receptors, transcription factors, and inflammation, successful transfer to human disease with positive outcomes in clinical trials is limited. This review provides an overview of novel targets addressed by clinical trials and gives an outlook on novel preclinical perspectives in PAH.

Harvard-Zitierstil: Sommer, N., Ghofrani, H., Pak, O., Bonnet, S., Provencher, S., Sitbon, O., et al. (2021) Current and future treatments of pulmonary arterial hypertension, British Journal of Pharmacology, 178(1), pp. 6-30. https://doi.org/10.1111/bph.15016

APA-Zitierstil: Sommer, N., Ghofrani, H., Pak, O., Bonnet, S., Provencher, S., Sitbon, O., Rosenkranz, S., Hoeper, M., & Kiely, D. (2021). Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology. 178(1), 6-30. https://doi.org/10.1111/bph.15016